Tag: financial results

Q2 2025 revenue of $40.2 million
Q2 2025 Adjusted EBITDA of $4.7 million and GAAP Net Income of $0.5 million
Paid off $14.9 million balance of 2025 Convertible Notes
Entered into a $15.0 million undrawn working capital facility for further operating flexibility and liquidity

HOUSTON, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Vaalco Energy, Inc. (NYSE: EGY; LSE: EGY) (“Vaalco” or the “Company”) today announced that it declared its quarterly cash dividend of $0.0625 per share of common stock for the third quarter of 2025 ($0.25 annualized), which is payable on September 19, 2025, to stockholders of record at the close of business on August 22, 2025. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors.

Management Board of Northern Horizon Capital AS has approved the unaudited financial results of Baltic Horizon Fund (the Fund) for the six months of 2025.

MATAWAN, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Hovnanian Enterprises, Inc. (NYSE: HOV), a leading national homebuilder, will release financial results for the third quarter ended July 31, 2025, the morning of Thursday, August 21, 2025. The Company will webcast its third quarter earnings conference call at 11:00 a.m. (ET) on Thursday, August 21, 2025.

Strong Growth in Business Fundamentals, Increased Brand Visibility, and New Strategic Conversations Signal Continued Momentum into Q3 and Q4 2025

GROSSE POINTE FARMS, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Saga Communications, Inc. (Nasdaq - SGA) (the “Company” or “Saga”) today reported that net revenue decreased 5.0% to $28.2 million for the quarter ended June 30, 2025 compared to $29.7 million for the same period last year. Station operating expense decreased 4.6% for the quarter to $22.2 million compared to the same period last year. For the quarter, operating income was $1.4 million compared to $2.1 million for the same quarter last year and station operating income (a non-GAAP financial measure) decreased 6.4% to $6.0 million. Capital expenditures were $1.3 million for the quarter compared to $1.5 million for the same period last year. We had net income of $1.1 million for the quarter compared to net income of $2.5 million for the second quarter last year. Diluted earnings per share were $0.18 in the second quarter of 2025.

FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2025, and provide a corporate update on August 14, 2025, at 8:30 a.m. Eastern Time.

Second Quarter Highlights – 2025 vs. 2024